Lupus-like membranous nephropathy: Is it lupus or not?

Ramin Sam, Amit Joshi, Sam James, Kuang-Yu Jen, Firouz Amani, Peter Hart, Melvin M. Schwartz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Membranous glomerulonephritis is typically classified as idiopathic or secondary to systemic lupus erythematosus (SLE), hepatitis B, drugs, toxins, other infections, or malignancy. Not infrequently in some patients without a definite diagnosis of SLE, pathologic features of secondary membranous nephropathy are seen e.g., mesangial and/or subendothelial deposits, tubuloreticular inclusions, and full house immunofluorescence. In these patients, there is uncertainty about the etiology, response to therapy, and prognosis of membranous GN. Methods: We retrospectively reviewed the charts of 98 patients with membranous GN at San Francisco General Hospital and John Stroger Hospital of Cook County over a 10-year period. Data were collected and analyzed using SPSS.18. Results: Thirty-nine (40 %) had idiopathic membranous GN (Group 1), thirty-six (37 %) had lupus membranous GN (Group 2) and twenty-three (23 %) had some pathological features of secondary membranous GN, but no definite etiology of membranous GN (Group 3). At baseline (at time of renal biopsy) and after mean follow-up of 3.5 years, the average serum creatinine (in mg/dL) in Group 1 was (1.6 ± 1.0 versus 1.6 ± 1.7), Group 2 was (1.8 ± 2.5 versus 1.2 ± 0.9) and Group 3 was (1.1 ± 0.4 versus 1.27 ± 0.83), respectively. For the same time points, the average urine protein to creatinine ratio (g/g) in Group 1 was (9.8 ± 7.1 versus 5.7 ± 6.7), Group 2 was (4.2 ± 3.9 versus 1.7 ± 2.2), and Group 3 was (7.4 ± 5.7 versus 3.1 ± 3.8). In addition, during the follow-up period, eleven of 39 (28 %) in Group 1, two of 36 (6 %) in Group 2, and three of 23 (13 %) in Group 3 progressed to end-stage renal disease and were started on dialysis. Conclusions: It appears that patients with lupus membranous GN have better renal prognosis than patients with idiopathic membranous GN. The renal prognosis for patients with pathological features of lupus membranous but no diagnosis of systemic lupus (lupus-like membranous GN) falls in between. Further studies are needed to determine if Group 3 patients can (a) definitively be classified as true idiopathic membranous GN or lupus membranous GN or (b) they have a separate disease from either M-type phospholipase A2 receptor membranous nephropathy or systemic lupus-induced membranous nephropathy.

Original languageEnglish (US)
Pages (from-to)395-402
Number of pages8
JournalClinical and Experimental Nephrology
Volume19
Issue number3
DOIs
StatePublished - Jun 17 2015
Externally publishedYes

Fingerprint

Membranous Glomerulonephritis
Kidney
Systemic Lupus Erythematosus
Phospholipase A2 Receptors
Creatinine
County Hospitals
San Francisco
Hepatitis B
General Hospitals
Chronic Kidney Failure
Uncertainty
Fluorescent Antibody Technique
Dialysis
Urine
Biopsy
Infection
Serum
Pharmaceutical Preparations

Keywords

  • Idiopathic membranous
  • Membranous GN
  • Pathological features of lupus membranous
  • Systemic lupus

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

Sam, R., Joshi, A., James, S., Jen, K-Y., Amani, F., Hart, P., & Schwartz, M. M. (2015). Lupus-like membranous nephropathy: Is it lupus or not? Clinical and Experimental Nephrology, 19(3), 395-402. https://doi.org/10.1007/s10157-014-1002-1

Lupus-like membranous nephropathy : Is it lupus or not? / Sam, Ramin; Joshi, Amit; James, Sam; Jen, Kuang-Yu; Amani, Firouz; Hart, Peter; Schwartz, Melvin M.

In: Clinical and Experimental Nephrology, Vol. 19, No. 3, 17.06.2015, p. 395-402.

Research output: Contribution to journalArticle

Sam, R, Joshi, A, James, S, Jen, K-Y, Amani, F, Hart, P & Schwartz, MM 2015, 'Lupus-like membranous nephropathy: Is it lupus or not?', Clinical and Experimental Nephrology, vol. 19, no. 3, pp. 395-402. https://doi.org/10.1007/s10157-014-1002-1
Sam, Ramin ; Joshi, Amit ; James, Sam ; Jen, Kuang-Yu ; Amani, Firouz ; Hart, Peter ; Schwartz, Melvin M. / Lupus-like membranous nephropathy : Is it lupus or not?. In: Clinical and Experimental Nephrology. 2015 ; Vol. 19, No. 3. pp. 395-402.
@article{ff6127251bdd47ca922a3af08fe38c16,
title = "Lupus-like membranous nephropathy: Is it lupus or not?",
abstract = "Background: Membranous glomerulonephritis is typically classified as idiopathic or secondary to systemic lupus erythematosus (SLE), hepatitis B, drugs, toxins, other infections, or malignancy. Not infrequently in some patients without a definite diagnosis of SLE, pathologic features of secondary membranous nephropathy are seen e.g., mesangial and/or subendothelial deposits, tubuloreticular inclusions, and full house immunofluorescence. In these patients, there is uncertainty about the etiology, response to therapy, and prognosis of membranous GN. Methods: We retrospectively reviewed the charts of 98 patients with membranous GN at San Francisco General Hospital and John Stroger Hospital of Cook County over a 10-year period. Data were collected and analyzed using SPSS.18. Results: Thirty-nine (40 {\%}) had idiopathic membranous GN (Group 1), thirty-six (37 {\%}) had lupus membranous GN (Group 2) and twenty-three (23 {\%}) had some pathological features of secondary membranous GN, but no definite etiology of membranous GN (Group 3). At baseline (at time of renal biopsy) and after mean follow-up of 3.5 years, the average serum creatinine (in mg/dL) in Group 1 was (1.6 ± 1.0 versus 1.6 ± 1.7), Group 2 was (1.8 ± 2.5 versus 1.2 ± 0.9) and Group 3 was (1.1 ± 0.4 versus 1.27 ± 0.83), respectively. For the same time points, the average urine protein to creatinine ratio (g/g) in Group 1 was (9.8 ± 7.1 versus 5.7 ± 6.7), Group 2 was (4.2 ± 3.9 versus 1.7 ± 2.2), and Group 3 was (7.4 ± 5.7 versus 3.1 ± 3.8). In addition, during the follow-up period, eleven of 39 (28 {\%}) in Group 1, two of 36 (6 {\%}) in Group 2, and three of 23 (13 {\%}) in Group 3 progressed to end-stage renal disease and were started on dialysis. Conclusions: It appears that patients with lupus membranous GN have better renal prognosis than patients with idiopathic membranous GN. The renal prognosis for patients with pathological features of lupus membranous but no diagnosis of systemic lupus (lupus-like membranous GN) falls in between. Further studies are needed to determine if Group 3 patients can (a) definitively be classified as true idiopathic membranous GN or lupus membranous GN or (b) they have a separate disease from either M-type phospholipase A2 receptor membranous nephropathy or systemic lupus-induced membranous nephropathy.",
keywords = "Idiopathic membranous, Membranous GN, Pathological features of lupus membranous, Systemic lupus",
author = "Ramin Sam and Amit Joshi and Sam James and Kuang-Yu Jen and Firouz Amani and Peter Hart and Schwartz, {Melvin M.}",
year = "2015",
month = "6",
day = "17",
doi = "10.1007/s10157-014-1002-1",
language = "English (US)",
volume = "19",
pages = "395--402",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Lupus-like membranous nephropathy

T2 - Is it lupus or not?

AU - Sam, Ramin

AU - Joshi, Amit

AU - James, Sam

AU - Jen, Kuang-Yu

AU - Amani, Firouz

AU - Hart, Peter

AU - Schwartz, Melvin M.

PY - 2015/6/17

Y1 - 2015/6/17

N2 - Background: Membranous glomerulonephritis is typically classified as idiopathic or secondary to systemic lupus erythematosus (SLE), hepatitis B, drugs, toxins, other infections, or malignancy. Not infrequently in some patients without a definite diagnosis of SLE, pathologic features of secondary membranous nephropathy are seen e.g., mesangial and/or subendothelial deposits, tubuloreticular inclusions, and full house immunofluorescence. In these patients, there is uncertainty about the etiology, response to therapy, and prognosis of membranous GN. Methods: We retrospectively reviewed the charts of 98 patients with membranous GN at San Francisco General Hospital and John Stroger Hospital of Cook County over a 10-year period. Data were collected and analyzed using SPSS.18. Results: Thirty-nine (40 %) had idiopathic membranous GN (Group 1), thirty-six (37 %) had lupus membranous GN (Group 2) and twenty-three (23 %) had some pathological features of secondary membranous GN, but no definite etiology of membranous GN (Group 3). At baseline (at time of renal biopsy) and after mean follow-up of 3.5 years, the average serum creatinine (in mg/dL) in Group 1 was (1.6 ± 1.0 versus 1.6 ± 1.7), Group 2 was (1.8 ± 2.5 versus 1.2 ± 0.9) and Group 3 was (1.1 ± 0.4 versus 1.27 ± 0.83), respectively. For the same time points, the average urine protein to creatinine ratio (g/g) in Group 1 was (9.8 ± 7.1 versus 5.7 ± 6.7), Group 2 was (4.2 ± 3.9 versus 1.7 ± 2.2), and Group 3 was (7.4 ± 5.7 versus 3.1 ± 3.8). In addition, during the follow-up period, eleven of 39 (28 %) in Group 1, two of 36 (6 %) in Group 2, and three of 23 (13 %) in Group 3 progressed to end-stage renal disease and were started on dialysis. Conclusions: It appears that patients with lupus membranous GN have better renal prognosis than patients with idiopathic membranous GN. The renal prognosis for patients with pathological features of lupus membranous but no diagnosis of systemic lupus (lupus-like membranous GN) falls in between. Further studies are needed to determine if Group 3 patients can (a) definitively be classified as true idiopathic membranous GN or lupus membranous GN or (b) they have a separate disease from either M-type phospholipase A2 receptor membranous nephropathy or systemic lupus-induced membranous nephropathy.

AB - Background: Membranous glomerulonephritis is typically classified as idiopathic or secondary to systemic lupus erythematosus (SLE), hepatitis B, drugs, toxins, other infections, or malignancy. Not infrequently in some patients without a definite diagnosis of SLE, pathologic features of secondary membranous nephropathy are seen e.g., mesangial and/or subendothelial deposits, tubuloreticular inclusions, and full house immunofluorescence. In these patients, there is uncertainty about the etiology, response to therapy, and prognosis of membranous GN. Methods: We retrospectively reviewed the charts of 98 patients with membranous GN at San Francisco General Hospital and John Stroger Hospital of Cook County over a 10-year period. Data were collected and analyzed using SPSS.18. Results: Thirty-nine (40 %) had idiopathic membranous GN (Group 1), thirty-six (37 %) had lupus membranous GN (Group 2) and twenty-three (23 %) had some pathological features of secondary membranous GN, but no definite etiology of membranous GN (Group 3). At baseline (at time of renal biopsy) and after mean follow-up of 3.5 years, the average serum creatinine (in mg/dL) in Group 1 was (1.6 ± 1.0 versus 1.6 ± 1.7), Group 2 was (1.8 ± 2.5 versus 1.2 ± 0.9) and Group 3 was (1.1 ± 0.4 versus 1.27 ± 0.83), respectively. For the same time points, the average urine protein to creatinine ratio (g/g) in Group 1 was (9.8 ± 7.1 versus 5.7 ± 6.7), Group 2 was (4.2 ± 3.9 versus 1.7 ± 2.2), and Group 3 was (7.4 ± 5.7 versus 3.1 ± 3.8). In addition, during the follow-up period, eleven of 39 (28 %) in Group 1, two of 36 (6 %) in Group 2, and three of 23 (13 %) in Group 3 progressed to end-stage renal disease and were started on dialysis. Conclusions: It appears that patients with lupus membranous GN have better renal prognosis than patients with idiopathic membranous GN. The renal prognosis for patients with pathological features of lupus membranous but no diagnosis of systemic lupus (lupus-like membranous GN) falls in between. Further studies are needed to determine if Group 3 patients can (a) definitively be classified as true idiopathic membranous GN or lupus membranous GN or (b) they have a separate disease from either M-type phospholipase A2 receptor membranous nephropathy or systemic lupus-induced membranous nephropathy.

KW - Idiopathic membranous

KW - Membranous GN

KW - Pathological features of lupus membranous

KW - Systemic lupus

UR - http://www.scopus.com/inward/record.url?scp=84937191423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937191423&partnerID=8YFLogxK

U2 - 10.1007/s10157-014-1002-1

DO - 10.1007/s10157-014-1002-1

M3 - Article

C2 - 24993947

AN - SCOPUS:84937191423

VL - 19

SP - 395

EP - 402

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 3

ER -